NCT03646864View on ClinicalTrials.gov

A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

September 19, 2019

Study Completion Date

September 19, 2019

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

ACT-541468

ACT-541468 will be orally administered as a tablet (50 mg strength) at a once daily (o.d.) dose of 50 mg in the evening.

OTHER

Placebo

Placebo will be orally administered as a tablet matching ACT-541468, o.d. in the evening.

Trial Locations (5)

10117

Advanced Sleep Research, Berlin

30159

Klinische Forschungsgruppe Nord, Hanover

48231

ZMS, Warendorf

48431

framol-med GmbH, Lungenpraxis, Rheinau

01069

Klinische Forschungsgruppe Nord, Dresden

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT03646864 - A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter